

STUDY PROTOCOL

Open Access



The effect of information about the benefits and harms of mammography on women's decision-making: study protocol for a randomized controlled trial

Misericòrdia Carles^{1,2,3†}, Montserrat Martínez-Alonso^{4†}, Anna Pons⁵, Maria José Pérez-Lacasta^{1,2}, Lilisbeth Perestelo-Pérez^{6,7,8}, Maria Sala^{8,9,10}, Carmen Vidal¹¹, Montse García¹¹, Ana Toledo-Chávarri^{8,12}, Núria Codern^{13,14}, Maria Feijoo-Cid¹⁵, Anabel Romero^{8,9,10}, Roger Pla^{2,16,17}, Jorge Soler-González^{5,18}, Xavier Castells^{8,9,10}, Montserrat Rué^{2,4,8*} on behalf of the InforMa Group

Abstract

Background: The decision to participate or not in breast cancer screening is complex due to the trade-off between the expected benefit of breast cancer mortality reduction and the major harm of overdiagnosis. It seems ethically necessary to inform women so that they can actively participate in decision-making and make an informed choice based on their values and preferences.

The objective of this study is to assess the effects of receiving information about the benefits and harms of screening on decision-making, in women approaching the age of invitation to mammography screening.

Methods: A two-stage, randomized controlled trial (RCT). In the first stage, 40 Basic Health Areas (BHAs) will be selected and randomized to intervention or control. In the second stage, women within each BHA will be randomly selected ($n = 400$). Four breast cancer screening programs (BCSPs) of the Spanish public health system, three in Catalonia and one in the Canary Islands will participate in the study. Women in the intervention arm will receive a leaflet with detailed information on the benefits and harms of screening using mammography. Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial examinations of the BCSP. The primary outcome is informed choice, a dichotomous variable that combines knowledge, attitudes, and intentions. Secondary outcomes include decisional conflict; confidence in the decision made; anxiety about screening participation; worry about breast cancer; anticipated regret; time perspective; perceived importance of benefits/harms of screening; perceived risk of breast cancer; and leaflet acceptability. Primary and secondary outcomes are assessed 2–3 weeks after the intervention.

Discussion: This is the first RCT that assesses the effect of informing about the benefits and harms of breast cancer screening in Spain in women facing the decision to be screened using mammography. It aims to assess the impact of information on several decisional outcomes and to contribute to paving the road towards shared decision-making in breast cancer screening in our country.

(Continued on next page)

* Correspondence: montse.rue@cmb.udl.cat

†Equal contributors

²Research Group on Economic Evaluation and Health (GRAES), Reus, Spain

⁴Department of Basic Medical Sciences, University of Lleida-IRBLLEIDA, Lleida, Spain

Full list of author information is available at the end of the article



© The Author(s). 2017 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

(Continued from previous page)

Trial registration: ClinicalTrials.gov registry, ID: NCT03046004. Retrospectively registered on 4 February 2017. Trial name: InforMa study.

Keywords: Screening, Breast cancer, Informed choice, Early detection, Decision aids

Background

Background and rationale

The objective of breast cancer screening is to find cancer at an early stage when it may be easier to treat. Evidence shows that screening reduces breast cancer mortality by around 20% [1]. However, screening can produce harms or undesired effects such as false-negative and false-positive results, and the overdiagnosis of tumors that would not cause health problems during the woman's lifetime in the absence of screening [1].

The decision to participate or not in breast cancer screening is complex. On the one hand, there is a trade-off between the expected benefit of breast cancer mortality reduction and the major harm of overdiagnosis. On the other hand, there is uncertainty on the magnitude of overdiagnosis, with an estimated frequency of 11% of breast cancer cases from a population perspective, and about 19% from the perspective of a woman invited to screening [1]. It seems ethically necessary to inform women so that they can actively participate in decision-making and make an informed choice based on their values and preferences.

The need to develop and test decision aids (DAs) for breast cancer screening is clear. DAs are tools that help people become involved in decision-making by making explicit the decision that needs to be made, providing information about the options and outcomes, and by clarifying personal values [2]. Information on cancer screening is often biased, incomplete and persuasive [3, 4]. Many health professionals think that informing women about screening harms may deter them from being screened, with negative consequences for them [5]. A systematic review by Hoffmann and Del Mar shows that women overestimate the benefits and underestimate the harms of screening [6]. In addition, women overestimate the risk of breast cancer and most of them have not been informed of the adverse effects of screening. This explains why the majority of women believe very strongly that screening is almost always a good idea and that finding cancer early saves lives [7].

We performed a systematic review of the effects of DAs about breast cancer screening in women aged 50 years or younger, facing the decision to be screened [8]. Only four studies were included in the review [9–12], three of them published in 2015, which can be explained by the recent development of DAs for breast cancer screening. Moreover, the DAs were designed in Australia, the USA, and

Germany, limiting the generalizability of the results to our country, Spain. The meta-analysis of these studies showed that DAs improve knowledge and promote informed decisions, but divergent results on decisional conflict and confidence in the decision were observed. We concluded that more research is needed for the improvement of DAs and for assessing its impact on women's decisions.

Prior to the start of the randomized controlled trial (RCT) we performed a qualitative study with focus groups of women and health professionals with the aim of testing and improving an informative leaflet for breast cancer screening [5]. The effect of this leaflet in women facing the decision to participate in breast cancer screening is being assessed in the on-going study described by the present protocol.

Objective

The objective of this study is to assess the effect of receiving information about the benefits and harms of breast cancer screening on informed choice and other decision-making outcomes in women approaching the age of invitation to mammography screening.

Trial design

The study is designed as a two-stage RCT. In order to reduce intragroup contamination, in the first stage, 40 Basic Health Areas (BHAs) from two regions of Spain are selected and randomized to intervention or control. BHAs are the elementary territorial units of the health care system where primary health care and health promotion actions are provided to the population. In the second stage, women within each BHA will be randomly selected. To the best of our knowledge this is the first multicenter RCT on the effect of providing balanced information for breast cancer screening in Spain prior to being invited to screening using mammography. The primary outcome is informed choice, a dichotomous outcome that combines knowledge with consistent attitudes and intentions [12].

A pilot study was carried out with 30 women to test the recruitment procedures and the data collection process. Questionnaires were also checked for understanding and acceptability.

This study protocol follows the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines (see Additional file 1).

Methods

Participants, interventions, and outcomes

Study setting

In Spain the National Health System provides universal and free health coverage, including early detection of breast cancer. All women resident in Spain aged 50 to 69 years are actively invited to participate in the population-based screening program by a written letter every 2 years. Breast cancer screening follows the European Guidelines for Quality Assurance in Mammographic Screening [13] and its results meet the required standards. The invitation letter contains basic information about the program, mostly about its benefits.

Four breast cancer screening programs (BCSPs) of the Spanish public health system, three in Catalonia and one in the Canary Islands will participate in the study. All the BHAs of the participating BCSPs will be stratified by socioeconomic level. For two of the BCSPs in Catalonia the strata will be quintiles of a deprivation index. For the third BCSP in Catalonia we performed a principal components analysis that indicated that immigration rate and percentage of population older than 64 years were the variables that better separated the BHAs. Based on these two dichotomized variables four strata will be obtained. For the Canary Islands, the BHA strata will be obtained considering the immigrant rate, the proximity to health care services, and a rural/urban categorical variable.

Five blocks of two BHAs (one intervention and one control) will be randomly selected from the socioeconomic strata in each BCSP, for a total of 40 BHAs. Random samples of 30 to 50 women will be obtained within each BHA. The size of the selected samples will depend on the number of eligible women in each BHA and on the observed participation in the pilot study. Women potentially eligible within the selected BHAs range from 15 to more than 300. If a selected BHA has less than 30 potentially eligible women, all the potentially eligible women of the nearest BHA within the same socioeconomic strata will be added before selection of the random sample. The target sample size is 10 women per BHA, a total of 400 women, 200 in the intervention and 200 in the control group.

Eligibility criteria

Inclusion criteria are being a woman aged 49–50 years who, in 2–4 months, will be invited to participate in the screening program for the first time. The participant BCSPs are managed by Hospital del Mar in Barcelona, the Cancer Prevention and Control Program of the Catalan Institute of Oncology, the Canary Islands Health Service, and the Lleida Health Region.

Women will be excluded if they have a personal history of breast cancer; have difficulty speaking Spanish

or Catalan; and have cognitive impairment that prevents them from understanding or completing the materials based on the interviewer's judgment. Women with a low literacy level will not be excluded.

Interventions

Women in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false-positive results and overdiagnosis) of screening. Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial examinations of the BCSP. The intervention leaflet is included in Additional file 2.

The intervention leaflet was drafted from existing published leaflets and its estimates of the effects of screening are drawn from published systematic reviews, clinical trials or observational studies. The leaflet was evaluated using a qualitative design with focus groups of women and health professionals [5]. We analyzed women's perception of the leaflet information on benefits and harms of screening, and also health care professionals' perceptions of the convenience of providing it. The leaflet was rewritten accordingly, and assessed for acceptability in a pilot study.

Outcomes

With the aim of comparability, the outcome measures follow the Hersch et al. study protocol [14] very closely and will be collected using two questionnaires (pre-intervention (Q1) and post-intervention (Q2)) which are included in Additional files 3 and 4, respectively. Most of the outcome measures will be obtained through validated scales that have shown suitability in previous studies. We have translated them to Catalan and Spanish. The post-intervention measures will be assessed at 2–4 weeks after the intervention.

Primary outcome

The primary outcome is informed choice. It is a dichotomous outcome defined as adequate knowledge and intentions consistent with attitudes (positive or negative) [12, 15–17]. It is included in Sections 2, 3, and 4 of the post-intervention survey. The proportion of women with an informed choice will be compared between the two study groups. The three component variables of informed choice: knowledge, attitudes, and intentions, will be analyzed and reported separately.

Knowledge

Conceptual and numerical knowledge will be assessed following the Hersch et al. study [12] adapted to the mortality, incidence, and outcomes of screening data of

our setting. The threshold to define adequate knowledge for informed choice is to score at least 50% of the available marks, including at least one numerical mark, on all the three screening outcome subscales that refer to mortality reduction, overdiagnosis, and false positives.

Screening attitudes

Screening attitudes will be measured using five items adapted from Dormandy et al. [18]. Each item ranges from *strongly negative* to *strongly positive* [17]. Total scores can range from 5 to 25. A positive attitude is defined as a total score ≥ 20 .

Screening intentions

Intentions to participate in screening will be measured with one question with five responses that will be dichotomized as categories 1–2 (responses *definitely will* and *will*) indicating “intending” to screen and categories 3–5 (responses *unsure*, *will not*, and *definitely will not*), indicating “not intending” to screen [19, 20].

Secondary outcomes

Secondary outcomes include decisional conflict; confidence in the decision made; anxiety about screening participation; worry about breast cancer; anticipated regret; time perspective; perceived importance of benefits/harms of screening; perceived risk of breast cancer; and leaflet acceptability. Secondary outcomes are included in Sections 5 to 7 of the post-intervention questionnaire. In addition, screening participation and reasons for non-participation will be assessed.

Decisional process (conflict and confidence)

Decision conflict will be assessed using the Decisional Conflict Scale (10-item low-literacy version) by O'Connor [21, 22]. The items' responses are *yes*, *no*, and *not sure*. Confidence in the decision made will be measured with three questions with five response options ranging from *very little* to *very much*.

Anxiety about screening participation

Anxiety will be measured with the six-item short form of the Spielberger State-Trait Anxiety Inventory [23] with four responses from *not at all* to *a lot*.

Worry about breast cancer

A single item will measure the women's level of worry about developing breast cancer, using four verbal response categories ranging from *not worried at all* to *very worried* [16, 17].

Anticipated regret

This will be measured with two items from a validated scale. The first measures inaction regret and the second

action regret. Both items have five response categories ranging from *strongly agree* to *strongly disagree* [24, 25].

Time perspective

This will be assessed using the short form of the Consideration of Future Consequences Scale [26]. It includes four-items with five response categories ranging from *strongly agree* to *strongly disagree*.

Perceived importance of screening benefits/harms

This will be assessed with three questions on the importance of avoiding a breast cancer death, being diagnosed and treated for a cancer that is not harmful, and having a false-positive result, when deciding screening participation [12]. The response options range from *very important* to *not at all important*.

Perceived personal risk of breast cancer

This will be measured with two questions, one about the perception of personal risk for developing breast cancer during lifetime, in absolute terms (with four response categories ranging from *no chance* to *high chance*) [12, 25] and relative to an average woman of the same age (using five response categories ranging from *much lower* to *much higher*) [12, 27].

Perceived personal chances of screening benefits/harms

This will be measured with three questions on the perceived personal chance of experiencing specific outcomes if they participate in screening, compared with an average screened woman [12, 28]. The response categories range from *much lower* to *much higher*.

Leaflet assessment

Both leaflets, intervention and control, will be assessed with five items, extracted from the nine items of Hersch et al. [12]: (1) Read the leaflet all the way through? (yes/no), (2) Length of the leaflet (responses range from *much too short* to *much too long*), (3) Balance of the leaflet (responses range from *clearly slanted towards screening* to *clearly slanted away from screening*), (4) The leaflet was clear and easy to understand (responses range from *strongly agree* to *strongly disagree*), and (5) Found the leaflet helpful in making decision (responses range from *strongly agree* to *strongly disagree*).

Screening participation

After women have been invited to undergo the screening mammogram, participation and reasons for non-participation will be obtained through the corresponding BCSPs. Reasons for non-participation will be categorized as: already had a mammogram elsewhere; did not receive invitation; on holiday; ill/hospitalized; postponed to next round; forgot appointment; already having treatment for

cancer; not interested; screening does not work; screening has adverse effects; other.

Participant timeline

The study time period is 1 July 2016 to 31 August 2017. Allocation of the BHAs to the intervention or control groups was established at the beginning of the study. The participant timeline is detailed in Fig. 1.

Sample size

The primary analysis will compare the proportion of women who make an informed choice in the two groups using a chi-square test and the 95% confidence interval of the difference of proportions. We have considered clinically relevant an absolute difference of 20%. Assuming that the proportion of one group is 50% (conservative scenario) and estimating an intraclass correlation coefficient equal to 0.1 (cluster sampling), in order to achieve an 80% power to detect a group difference of 20%, with a two-sided significance level of 5%, a sample size of 200 women

per group is required. The 400 women will be distributed in 100 per each BCSP. This sample size is sufficient to detect a difference of 20% in the secondary outcome intention to participate and a mean difference of 0.35 standard deviations in the knowledge and attitudes scales. Assuming that 60% of women invited to participate will accept and 20% will be lost to follow-up, a minimum of 840 women, 210 per BCSP, will be invited.

Recruitment

All selected women will receive a mailed invitation letter with a summary of the study objectives. In an interval of 2 weeks, a phone call will be made where trained interviewers briefly introduce and describe the study and determine eligibility (assessment of the inclusion/exclusion criteria). The interviewers will inform the women that participation consists of answering two questionnaires, either via web or by phone with a prior mailing of the questionnaires. Consent will be obtained orally and women will be told they can leave the study at any

	STUDY PERIOD			
	Previous 1-2 weeks	Baseline	2-3 weeks post- intervention	At 3-months after completing accrual
ENROLMENT:				
Eligibility screen	X			
Informed consent	X			
ASSESSMENTS:				
Socio-demographic		X		
Information technologies use and medical literacy		X		
BC risk factors		X		
BC screening experience		X		
General BC screening knowledge, attitudes and participation intentions		X		
Leaflet utilization and acceptability			X	
Informed choice, screening knowledge, attitudes and participation intentions			X	
Decision process and confidence			X	
Anxiety			X	
Anticipated regret and time perspective			X	
Perceived importance and personal chances of screening benefits and harms			X	
Perceived personal risk of BC			X	
Screening participation				X

Fig. 1 Summary of enrollment, interventions, variable assessments, and timing for measurements (SPIRIT Figure). Allocation is established at the beginning of the study

time, with no effect on being invited to the screening program.

Assignment of interventions

Allocation

Sequence generation, allocation concealment and implementation

In order to reduce the intragroup contamination, the first stage of sampling will randomly assign 10 BHAs of each screening program to the intervention and control groups. In total, 20 BHAs will be assigned to each study group using computer-generated blocks of size 2. In the second stage, the public system health registries will be used to select the target population using a computer-generated sequence of random numbers.

The random allocation sequence will be generated by a statistician with no contact with the participants (MR). The interviewers responsible for the recruitment of participants will not be aware of the women's allocation.

Blinding

It will not be possible to blind the intervention to the interviewers and participants. The interviewers will be independent of the research team and, for women who choose answering by phone, the interviews will follow a structured outline and will be continuously monitored by the study team. Statistical analyses and drawing of conclusions from these will be conducted on an intention-to-treat basis and according to the study protocol. The data analysts will be blinded to intervention status.

Data collection, management, and analysis

Data collection methods

After acceptance, the first questionnaire (Q1) will be sent to the study participants. Q1 is included in the Additional file 3 and has the following sections: (1) sociodemographic data (including education level and work situation), (2) previous screening experience (opportunistic screening use, if applicable, periodicity of mammographic examinations, previous breast lesions, previous diagnostic tests for breast lesions), (3) risk factors of breast cancer (age at menarche, reproductive history, age at menopause, if applicable, use of hormone replacement therapy, use of oral contraceptive drugs, and family history of breast cancer), (4) use of information technologies, (5) general screening knowledge, (6) screening attitudes, (7) screening intentions, and (8) medical literacy according to the short version of the European Health Literacy Survey Questionnaire (HLS-EU-Q16) [29].

The post-intervention questionnaire (Q2) has the following sections: (1) leaflet acceptability, (2) screening knowledge, (3) screening attitudes, (4) screening intentions, (5) decision process, (6) decisional confidence, (7)

anxiety, (8) anticipated regret, (9) time perspective, (10) perceived importance of benefits and harms, (11) perceived personal chances of screening benefits and harms, and (12) perceived personal risk of breast cancer. Participation in the screening program will be assessed at 3 months after completing accrual.

Data management

All the data will be entered and recorded with the open source LimeSurvey [30]. Range checks and error alerts will be used to prevent invalid data. R software will be used for data analysis [31].

Statistical methods

Primary and secondary outcomes in the two study groups will be compared using the chi-square test for categorical variables and the Student's *t* and Mann-Whitney *U* tests for quantitative variables. These standard tests will be adjusted for the inflation in variance that can be attributed to clustering of responses within BHAs [32]. Multivariate mixed-effects models [33] will be used to assess the effect of the intervention on the outcomes accounting for women's characteristics and the intracluster correlation induced by the BHAs. If missing values reduce the sample size by more than 10%, multiple imputation and sensitivity analysis will be used. No subgroup analyses will be performed.

Discussion

This is the first RCT trial assessing the effect of informing about the benefits and harms of breast cancer screening in Spain in women facing the decision to be screened using mammography. The leaflet used in the intervention arm is based on current evidence from systematic reviews and has been adapted to local data on incidence and mortality.

In the qualitative study designed for developing the leaflet of the intervention group, women showed a lack of knowledge of the existence of overdiagnosis and surprise that they had not been informed of this issue [5]. The current study aims to assess the impact of informing Spanish women on several decisional outcomes and contribute to paving the road towards shared decision-making in breast cancer screening in our country.

With the aim of comparability, the outcome measures follow very closely the Hersch et al. study protocol [14]. Most of the outcome measures are obtained through validated scales that have been used in previous studies.

One of the study limitations is that the intervention may not reach women with low literacy or who are recent immigrants. Moreover, the intervention leaflet may not meet the needs of some population groups, such as people with cognitive impairment, to understand

or complete the materials or persons who do not speak Spanish or Catalan.

Trial status

As of 30 June 2017, we have enrolled 335 of our target 400 participants in the study.

Additional files

Additional file 1: SPIRIT Checklist. Checklist of the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines. (PDF 99 kb)

Additional file 2: Study leaflet. Leaflet with detailed information on the benefits and harms of screening with mammography, used in the intervention arm of the study. (PDF 791 kb)

Additional file 3: Pre-intervention questionnaire (Q1). Baseline characteristics of participants. (PDF 253 kb)

Additional file 4: Post-intervention questionnaire (Q2). Study outcomes. (PDF 298 kb)

Abbreviations

BCSP: Breast cancer screening program; BHA: Basic Health Area; DA: Decision aids; HLS-EU-Q16: European Health Literacy Survey Questionnaire-short version; ICMJE: International Committee of Medical Journal Editors; ID: Identifier; Q1: Pre-intervention questionnaire; Q2: Post-intervention questionnaire; RCT: Randomized controlled trial

Acknowledgements

We are indebted to Francesc Macià, Montse Llorens, Mariola de la Vega and Juan Manuel González for collaborating in the selection of BHAs and participating women.

Members of the InforMa Study Group (alphabetical order): ÀreaQ, Evaluation and Qualitative Research, Barcelona: Àngels Cardona and Núria Codern; Canary Islands Health Service (SESCS): Lilisbeth Perestelo-Pérez and Ana Toledo-Chávarri; Universitat Autònoma de Barcelona (UAB): Maria Feijoo; Cancer Prevention and Control Program, Catalan Institute of Oncology, L'Hospitalet de Llobregat: Montse García and Carmen Vidal; IRBLLEIDA-Universitat de Lleida: Sara Buil, Clara Viñals, Laia Viñals, Montserrat Martínez-Alonso, Marta Ortega, Sandra Pla, Anna Pons-Rodríguez, Montserrat Rué, and Jorge Soler; URV (University Rovira i Virgili), Reus: Misericòrdia Carles, Maria José Pérez, and Roger Pla; IMIM, Hospital del Mar Medical Research Institute, Barcelona: Andrea Burón, Xavier Castells, Anabel Romero, and Maria Sala.

Funding

This work is supported by the research grant "Women participation in decisions and strategies on early detection of breast cancer" (PI14/00113) from the Instituto de Salud Carlos III and cofunded by Fondo Europeo de Desarrollo Regional (FEDER) "Una manera de hacer Europa." Anna Pons received a grant for PhD students from the Lleida Biomedical Research Institute (IRBLLEIDA). The funders will not participate in the study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication.

Availability of data and materials

Not applicable

Data sharing and dissemination

All the data and code (in R) will be deposited online for reproducibility under a creative commons license (e.g., *figshare* with *github* integration or similar). The results of the trial will be presented at national and international conferences relevant to the subject field and will be submitted to international peer-reviewed journals. The trial will be reported in accordance with the Consolidated Standards of Reporting Trials (CONSORT) Statement [34].

Authors' contributions

MR, MC, MMA, and MJP designed the study. LP, MS, MG, CV, and AR coordinated the study sample selection and participated actively in the questionnaires design.

AT, NC, and MF coordinated and actively participated in the elaboration of the leaflet for the intervention group. RP, JS, and XC provided feedback on the quantification and presentation of the benefits and harms of breast cancer screening in the intervention leaflet. All authors contributed to discussion and revisions to the study design. MR, MMA, and AP drafted the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the Ethics Committees of the hospitals Universitari Arnau de Vilanova, in Lleida and Parc de Salut Mar in Barcelona (approval numbers 19/2014 and 2014/5998/I, respectively), and by the Scientific and Ethics Committee of the University Hospital Nuestra Señora de la Candelaria, in Tenerife (Canary Islands, Spain). The study is performed in accordance with Good Clinical Practice and the Declaration of Helsinki. Informed consent will be obtained by phone after verifying that the inclusion criteria are met and it will be documented by the interviewer. All participants will be assigned an ID number and all the questionnaires and datasets will be anonymized. Only the study team will have access to the document that links study ID with participant names. All the study files are electronic and will be stored on secure servers on password-protected computers.

Consent for publication

Not applicable

Competing interests

All authors have completed the International Committee of Medical Journal Editors (ICMJE) uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: funding from the Spanish Ministry of Health and the Biomedical Research Institute of Lleida (IRBLLEIDA) as described below; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Economics, University Rovira i Virgili, Reus, Spain. ²Research Group on Economic Evaluation and Health (GRAES), Reus, Spain. ³Research Centre on Industrial and Public Economics, (CREIP), Reus, Spain. ⁴Department of Basic Medical Sciences, University of Lleida-IRBLLEIDA, Lleida, Spain. ⁵Lleida Biomedical Research Institute (IRBLLEIDA), Lleida, Spain. ⁶Evaluation Unit of the Canary Islands Health Service (SESCS), Tenerife, Spain. ⁷Center for Biomedical Research of the Canary Islands (CIBICAN), Tenerife, Spain. ⁸Health Services Research on Chronic Patients Network (REDISSEC), Madrid, Spain. ⁹Epidemiology and Evaluation Department, Hospital del Mar, Barcelona, Spain. ¹⁰IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. ¹¹Cancer Prevention and Control Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Spain. ¹²Canary Islands Foundation of Health Research (FUNCANIS), Tenerife, Spain. ¹³ÀreaQ, Evaluation and Qualitative Research, Barcelona, Spain. ¹⁴Nursing and Occupational Therapy School (EUIT), Terrassa, Universitat Autònoma de Barcelona, Barcelona, Spain. ¹⁵Department of Nursing, Faculty of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain. ¹⁶Catalan Health Service, Tarragona Region, Tarragona, Spain. ¹⁷Medical School, University Rovira i Virgili, Reus, Spain. ¹⁸Department of Medicine, University of Lleida, Lleida, Spain.

Received: 1 July 2017 Accepted: 25 August 2017

Published online: 12 September 2017

References

- Marmot MG, Altman DG, Cameron D, Dewar J, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. *Br J Cancer*. 2013;108:2205–40.
- Patient decision aids [Internet]. Ottawa: The Ottawa Hospital Research Institute; c2015 [cited 2017 Jun 25]. Available from: <https://decisionaid.ohri.ca/>. Accessed 4 Sept 2017.

3. Steckelberg A, Hülpenhaus C, Haastert B, Mühlhauser I. Effect of evidence based risk information on "informed choice" in colorectal cancer screening: randomised controlled trial. *BMJ*. 2011;342:d3193.
4. Hoffman RM, Elmore JG, Fairfield KM, Gerstein BS, Levin C, Pignone MP. Lack of shared decision making in cancer screening discussions. Results from a national survey. *Am J Prev Med*. 2014;47:251–9.
5. Toledo-Chávarri A, Rué M, Codern-Bové N, Carles-Lavila M, Perestelo-Pérez L, Pérez-Lacasta M, Feijoo-Cid M. A qualitative study on a decision aid for breast cancer screening: views from women and health professionals. *Eur J Cancer Care*. 2017;26:e12660.
6. Hoffmann TC, Del Mar C. Patients' expectations of the benefits and harms of treatments, screening, and tests. *JAMA Intern Med*. 2015;175:274–86.
7. Stefanek ME. Uninformed compliance or informed choice? A needed shift in our approach to cancer screening. *J Natl Cancer Inst*. 2011;103:1821–6.
8. Martínez-Alonso M, Carles-Lavila M, Pérez-Lacasta MJ, Pons-Rodríguez A, García M, Rué M, on behalf of the InforMa Group. Assessment of the effects of decision aids about breast cancer screening: a systematic review and meta-analysis. *BMJ Open*. 2017. <http://dx.doi.org/10.1136/bmjopen-2017-016894>.
9. Mathieu E, Barratt AL, McGeehan K, Davey HM, Howard K, Houssami N. Helping women make choices about mammography screening: an online randomized trial of a decision aid for 40-year-old women. *Patient Educ Couns*. 2010;81:63–72.
10. Eden KB, Scariati P, Klein K, Watson L, Remiker M, Hribar M, Forro V, Michaels L, Nelson HD. Mammography decision aid reduces decisional conflict for women in their forties considering screening. *J Womens Health*. 2015;24:1013–20.
11. Gummertsbach E, in der Schmitt J, Mortsiefer A, Abholz H-H, Wegscheider K, Pentzek M. Willingness to participate in mammography screening: a randomized controlled questionnaire study of responses to two patient information leaflets with different factual content. *Dtsch Arztebl Int*. 2015;112:61–8.
12. Hersch J, Barratt A, Jansen J, Irwig L, McGeehan K, Jacklyn G, et al. Use of a decision aid including information on overdiagnosis to support informed choice about breast cancer screening: a randomised controlled trial. *Lancet*. 2015;385:1642–52.
13. Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L, European Commission. European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis. 4th ed. Luxembourg: Office for Official Publications of the European Communities; 2006.
14. Hersch J, Barratt A, Jansen J, Houssami N, Irwig L, Jacklyn G, et al. The effect of information about overdiagnosis of breast cancer on women's decision-making about mammography screening: study protocol for a randomised controlled trial. *BMJ Open*. 2014;4:e004990.
15. Marteau TM, Dormandy E, Michie S. A measure of informed choice. *Health Expect*. 2001;4:99–108.
16. Mathieu E, Barratt A, Davey HM. Informed choice in mammography screening. *Arch Intern Med*. 2007;167:2039–46.
17. Smith SK, Trevena L, Simpson JM, Barratt A, Nutbeam D, McCaffery KJ. A decision aid to support informed choices about bowel cancer screening among adults with low education: randomised controlled trial. *BMJ*. 2010;341:c5370.
18. Dormandy E, Michie S, Hooper R, Marteau TM. Informed choice in antenatal Down syndrome screening: a cluster-randomised trial of combined versus separate visit testing. *Patient Educ Couns*. 2006;61:56–64.
19. Gwyn K, Vernon SW, Conoley PM. Intention to pursue genetic testing for breast cancer among women due for screening mammography. *Cancer Epidemiol Biomarkers Prev*. 2003;12:96–102.
20. Watson E, Hewitson P, Brett J, Bukach C, Evans R, Edwards A, et al. Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: a randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested. *Patient Educ Couns*. 2006;63:367–79.
21. O'Connor AM. Decisional Conflict Scale—user manual 1993 [updated 2010]. Decision aid evaluation measures. http://decisionaid.ohri.ca/eval_dcs.html. Accessed 4 Sept 2017.
22. O'Connor AM. Decision Self-Efficacy Scale—user manual 1995 [updated 2002]. Decision aid evaluation measures. http://decisionaid.ohri.ca/eval_self.html. Accessed 4 Sept 2017.
23. Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). *Br J Clin Psychol*. 1992;31:301–6.
24. Sandberg T, Conner M. A mere measurement effect for anticipated regret: impacts on cervical screening attendance. *Br J Soc Psychol*. 2009;48:221–36.
25. Ziarnowski KL, Brewer NT, Weber B. Present choices, future outcomes: anticipated regret and HPV vaccination. *Prev Med*. 2009;48:411–4.
26. von Wagner C, Good A, Smith SG, Wardle J. Responses to procedural information about colorectal cancer screening using faecal occult blood testing: the role of consideration of future consequences. *Health Expect*. 2012;15:176–86.
27. Lipkus IM, Biradavolu M, Fenn K, Keller P, Rimer BK. Informing women about their breast cancer risks: truth and consequences. *Health Commun*. 2001;13:205–26.
28. Longman T, Turner RM, King M, McCaffery KJ. The effects of communicating uncertainty in quantitative health risk estimates. *Patient Educ Couns*. 2014;89:252–9.
29. The HLS-EU Consortium 2012. Measurement of health literacy in Europe: HLS-EU-Q47; HLS-EU-Q16; and HLS-EU-Q86. Health Literacy Project 2009–2012 [Internet]; c2012. Available from: <http://www.forumitesss.com/wp-content/uploads/2015/02/HLS-EU-Q-tools-and-introduction-2.pdf>. Accessed 4 Sept 2017.
30. LimeSurvey GmbH. LimeSurvey: an open source survey tool [Internet]. Hamburg, Germany: LimeSurvey GmbH; 2003. Available from: <http://www.limesurvey.org>. Accessed 4 Sept 2017.
31. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2017. Available from: <https://www.R-project.org/>. Accessed 4 Sept 2017.
32. Donner A, Klar N. Design and analysis of cluster randomization trials in health research. London: Arnold; 2000.
33. Pinheiro JC, Bates DM. Mixed-effects models in S and S-plus. New York: Springer-Verlag New York, Inc.; 2000.
34. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010;340:c332.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

